Abstract
Objectives To summarize information on anti-aging substances and nanotechnology formulations against aging and to unveil emerging anti-aging approaches like gene therapy, stem cells, monoclonal antibodies, and future trends.
Methods A systematic literature search was conducted through May 10, 2021. Eligibility criteria were articles in English relevant to the aim of this review.
Results Anti-aging substances like coenzyme Q10, curcumin, ginsenoside Rg1, bioidentical hormones, and geroprotectants, can help to slow the aging process. Nano-delivery of anti-aging substances are novel approaches able to delay aging. Cryogenic sleep, therapeutic hypothermia, and caloric restriction are promising interventions that may one day grant humans biological immortality.
Discussion The ability to target basic maturation mechanisms, such as responses to oxidative damage, inflammation, irritation, and senescence associated with multiple concurrent deficits, is the most important feature. Nanocarriers to transport bioactive compounds have been shown to improve their stability, increase intestinal absorption, and prolong their circulation time.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
